With the recent FDA clearance of two over-the-counter sensors following significant automated insulin pump integrations, 2024 has been full of good news for the company.
Speaking to Drug Delivery Business News at the American Diabetes Association Scientific Sessions in Orlando, Abbott Diabetes SVP of Commercial Operations, Chris Scoggins, said the company wants to keep that momentum going.
“2024 is shaping up to be an exciting year, a good year,” Scoggins said. “The excitement for us, at least in the U.S., is that we’re just pushing deeper and deeper into this really big, underserved patient population of people with type 2 diabetes.”
Get the full story at our sister site, Drug Delivery Business News.
